{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination effectively triggers local type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination broadens the tumor immunopeptidome and MHC-I presentation.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "mRNA vaccination improves subsequent sensitivity to checkpoint blockade therapies.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        },
        {
          "quote": "5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models."
    },
    {
      "claim_id": "C04",
      "claim": "Human patients with prior mRNA vaccination have improved outcomes under ICI therapy.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation."
    }
  ]
}